{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:08:43Z","timestamp":1783642123088,"version":"3.55.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2020R1A2C1010293"],"award-info":[{"award-number":["2020R1A2C1010293"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.afos.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:09:02Z","timestamp":1655442542000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of sex steroids on osteonecrosis of the jaw"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-1234","authenticated-orcid":false,"given":"Ranhee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4689-1323","authenticated-orcid":false,"given":"Sung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5623-6368","authenticated-orcid":false,"given":"Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-854X","authenticated-orcid":false,"given":"Seung-Yup","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2022.05.003_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2004.11.097","article-title":"Mechanisms of sex steroid effects on bone","volume":"328","author":"Syed","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.afos.2022.05.003_bib2","first-page":"298","article-title":"Postmenopausal osteoporosis","volume":"55","author":"Albright","year":"1940","journal-title":"Trans A Amer Phys"},{"key":"10.1016\/j.afos.2022.05.003_bib3","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2022.05.003_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.afos.2022.05.003_bib7","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib8","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201343","article-title":"Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor?","volume":"13","author":"Soutome","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.afos.2022.05.003_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2022.05.003_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00198-018-4775-3","article-title":"Long waiting time before tooth extraction may increase delayed wound healing in elderly Japanese","volume":"30","author":"Kamimura","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2022.05.003_bib12","doi-asserted-by":"crossref","first-page":"17226","DOI":"10.1038\/s41598-021-96480-8","article-title":"Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients","volume":"11","author":"Soutome","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.afos.2022.05.003_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J\u00a0Cranio-Maxillo-Fac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J\u00a0Int Soc Prev Community Dent"},{"key":"10.1016\/j.afos.2022.05.003_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1620\/tjem.247.75","article-title":"Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone","volume":"247","author":"Shibahara","year":"2019","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.afos.2022.05.003_bib16","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.biomaterials.2012.11.003","article-title":"The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomised rat model","volume":"34","author":"Cardemil","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.afos.2022.05.003_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/157489206778776989","article-title":"Last generation of amino-bisphosphonates (N-BPs) and cancer angiogenesis: a new role for these drugs?","volume":"1","author":"Santini","year":"2006","journal-title":"Recent Pat Anticancer Drug Disc"},{"key":"10.1016\/j.afos.2022.05.003_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hon.819","article-title":"Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells","volume":"25","author":"Allegra","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw002","article-title":"Regorafenib also can cause osteonecrosis of the jaw","volume":"108","author":"Antonuzzo","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.afos.2022.05.003_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1601-0825.2010.01739.x","article-title":"In\u00a0vivo effects of zoledronic acid on oral mucosal epithelial cells","volume":"17","author":"Allam","year":"2011","journal-title":"Oral Dis"},{"key":"10.1016\/j.afos.2022.05.003_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.afos.2022.05.003_bib22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.joms.2012.12.005","article-title":"Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw?","volume":"71","author":"Kos","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/cancers14020330","article-title":"Macrophage involvement in medication-related osteonecrosis of the jaw (MRONJ): a comprehensive, short review","volume":"14","author":"Gkouveris","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.afos.2022.05.003_bib24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/medicina57050463","article-title":"Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ)","volume":"57","author":"Otto","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.afos.2022.05.003_bib25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.afos.2022.05.003_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.afos.2022.05.003_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.afos.2022.05.003_bib28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.afos.2022.05.003_bib29","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1073\/pnas.1533500100","article-title":"Suppressive function of androgen receptor in bone resorption","volume":"100","author":"Kawano","year":"2003","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.afos.2022.05.003_bib30","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1073\/pnas.88.12.5134","article-title":"Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells","volume":"88","author":"Pacifici","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.afos.2022.05.003_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1172\/JCI116179","article-title":"Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors","volume":"91","author":"Tanaka","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.afos.2022.05.003_bib32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm1096-1132","article-title":"Estrogen promotes apoptosis of murine osteoclasts mediated by TGF\u2013\u03b2","volume":"2","author":"Hughes","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.afos.2022.05.003_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.186.4.489","article-title":"Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts","volume":"186","author":"Kameda","year":"1997","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.afos.2022.05.003_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.afos.2022.05.003_bib35","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3390\/ijms20102557","article-title":"Molecular-based treatment strategies for osteoporosis: a literature review","volume":"20","author":"Ukon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.afos.2022.05.003_bib36","first-page":"719","article-title":"Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity","volume":"104","author":"Kousteni","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.afos.2022.05.003_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1749-6632.2002.tb04109.x","article-title":"Src is an initial target of sex steroid hormone action","volume":"963","author":"Migliaccio","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.afos.2022.05.003_bib38","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/me.2007-0259","article-title":"Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism","volume":"21","author":"Manolagas","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib39","doi-asserted-by":"crossref","first-page":"27285","DOI":"10.1074\/jbc.M702810200","article-title":"Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids","volume":"282","author":"Almeida","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.afos.2022.05.003_bib40","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm.1954","article-title":"Inhibition of osteoblastic bone formation by nuclear factor-kappaB","volume":"15","author":"Chang","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.afos.2022.05.003_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jbmr.128","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and in men","volume":"26","author":"Modder","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2022.05.003_bib42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.afos.2022.05.003_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.afos.2022.05.003_bib44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.afos.2022.05.003_bib45","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","article-title":"Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1470269","article-title":"Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells","volume":"147","author":"Hofbauer","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib47","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1172\/JCI117995","article-title":"Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor","volume":"95","author":"Bellido","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.afos.2022.05.003_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.steroids.2008.10.003","article-title":"Androgens and bone","volume":"74","author":"Clarke","year":"2009","journal-title":"Steroids"},{"key":"10.1016\/j.afos.2022.05.003_bib49","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jbmr.5650051114","article-title":"Effects of androgens on parathyroid hormone and interleukin-1-stimulated prostaglandin production in cultured neonatal mouse calvariae","volume":"5","author":"Pilbeam","year":"1990","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2022.05.003_bib50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/jbmr.1997.12.3.464","article-title":"Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in\u00a0vitro","volume":"12","author":"Kasperk","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.afos.2022.05.003_bib51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-2143(97)90132-3","article-title":"Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens","volume":"130","author":"Glueck","year":"1997","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.afos.2022.05.003_bib52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MBC.0000000000000047","article-title":"Testosterone, anastrozole, factor V Leiden heterozygosity and osteonecrosis of the jaws","volume":"25","author":"Pandit","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.afos.2022.05.003_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12878-017-0076-x","article-title":"Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy","volume":"17","author":"Jarman","year":"2017","journal-title":"BMC Hematol"},{"key":"10.1016\/j.afos.2022.05.003_bib54","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1210\/jcem-67-5-937","article-title":"Effect of excess endogenous androgens on bone density in young women","volume":"67","author":"Buchanan","year":"1988","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.afos.2022.05.003_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2265.1989.tb02235.x","article-title":"Bone mass in hirsute women with androgen excess","volume":"30","author":"Dixon","year":"1989","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0015-0282(16)54837-7","article-title":"Polycystic ovaries as a relative protective factor for bone mineral loss in young women with amenorrhea","volume":"57","author":"Di Carlo","year":"1992","journal-title":"Fertil Steril"},{"key":"10.1016\/j.afos.2022.05.003_bib57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF00571330","article-title":"Bone mineral density in hyperandrogenic amenorrhoea","volume":"52","author":"Pre\u017eelj","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2022.05.003_bib58","first-page":"2821","article-title":"Augmentation of bone mineral density in hirsute women","volume":"82","author":"Dagogo-Jack","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.1998.3691182.x","article-title":"Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women","volume":"48","author":"Adami","year":"1998","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0015-0282(99)00203-4","article-title":"Bone mineral density and body composition in lean women with polycystic ovary syndrome","volume":"72","author":"Good","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.afos.2022.05.003_bib61","first-page":"135","volume":"vol. 28","author":"Zborowski","year":"2001"},{"key":"10.1016\/j.afos.2022.05.003_bib62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0026-0495(96)90229-2","article-title":"Menstrual history as a determinant of current bone density in young hirsute women","volume":"45","author":"Castelo-Branco","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.afos.2022.05.003_bib63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-2007-1000771","article-title":"Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess","volume":"26","author":"Pre\u017eelj","year":"1994","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.afos.2022.05.003_bib64","first-page":"1250","article-title":"Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist","volume":"84","author":"Moghetti","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s007740170043","volume":"19","author":"Seeman","year":"2001","journal-title":"Raloxifene. J Bone Miner Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib66","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2013-4119","article-title":"The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib67","first-page":"423","article-title":"Osteonecrosis of the jaw in a patient on raloxifene: a case report","volume":"46","author":"Baur","year":"2015","journal-title":"Quintessence Int"},{"key":"10.1016\/j.afos.2022.05.003_bib68","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1097\/SCS.0000000000004278","article-title":"Mandibular osteonecrosis associated with raloxifene","volume":"29","author":"Pontes","year":"2018","journal-title":"J\u00a0Craniofac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib69","first-page":"2","article-title":"Raloxifene-induced osteonecrosis of the jaw (MRONJ) with no exposure to bisphosphonates: clinical and radiographic findings","author":"Bindakhil","year":"2021","journal-title":"Quintessence Int"},{"key":"10.1016\/j.afos.2022.05.003_bib70","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1038\/s41598-020-68037-8","article-title":"Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.afos.2022.05.003_bib71","first-page":"1029","article-title":"Aromatase inhibitors and bone loss","volume":"20","author":"Perez","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.afos.2022.05.003_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J\u00a0Oncol Prac"},{"key":"10.1016\/j.afos.2022.05.003_bib73","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jcms.2014.08.002","article-title":"Potential significance of antiestrogen therapy in the development of bisphosphonate related osteonecrosis of the jaw","volume":"42","author":"Vaszilko","year":"2014","journal-title":"J\u00a0Cranio-Maxillo-Fac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib74","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","article-title":"Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals","volume":"42","author":"Neha","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.afos.2022.05.003_bib75","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0015-0282(16)54948-6","article-title":"Gonadotropin-releasing hormone agonists and the skeleton","volume":"57","author":"Wallach","year":"1992","journal-title":"Fertil Steril"},{"key":"10.1016\/j.afos.2022.05.003_bib76","series-title":"Fertility preservation in oncological and non-oncological diseases : a practical guide","first-page":"215","article-title":"GnRH agonist","author":"Nawroth","year":"2020"},{"key":"10.1016\/j.afos.2022.05.003_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008475","article-title":"Gonadotrophin-releasing hormone analogues for pain associated with endometriosis","author":"Brown","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.afos.2022.05.003_bib78","first-page":"3","article-title":"Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study","volume":"14","author":"Gerhard","year":"1992","journal-title":"Clin Ther"},{"key":"10.1016\/j.afos.2022.05.003_bib79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0015-0282(16)60782-3","article-title":"Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol","volume":"52","author":"Dawood","year":"1989","journal-title":"Fertil Steril"},{"key":"10.1016\/j.afos.2022.05.003_bib80","first-page":"410","article-title":"Bone mass in endometriosis patients treated with GnRH agonist implant or danazol","volume":"77","author":"Dodin","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.afos.2022.05.003_bib81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2265.1990.tb00501.x","article-title":"The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis","volume":"33","author":"Whitehouse","year":"1990","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00006254-199603000-00020","article-title":"Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis","volume":"51","author":"Kiilholma","year":"1996","journal-title":"Obstetrical & gynecological survey"},{"key":"10.1016\/j.afos.2022.05.003_bib83","article-title":"Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density","author":"Sagsveen","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.afos.2022.05.003_bib84","first-page":"558","article-title":"Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial","volume":"75","author":"Surrey","year":"1992","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib85","first-page":"1219","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.afos.2022.05.003_bib86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.afos.2022.05.003_bib87","first-page":"2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib88","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib89","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1038\/s41598-021-82824-x","article-title":"Effect of tamoxifen with or without gonadotropin-releasing hormone analog on DXA values in women with breast cancer","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.afos.2022.05.003_bib90","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2022.05.003_bib91","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2022.05.003_bib92","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bone.2010.05.038","article-title":"Treatment and prevention of bone complications from prostate cancer","volume":"48","author":"Lee","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.afos.2022.05.003_bib94","doi-asserted-by":"crossref","first-page":"115650","DOI":"10.1016\/j.bone.2020.115650","article-title":"Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: a nationwide cohort-study","volume":"143","author":"Kim","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.afos.2022.05.003_bib95","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00198-017-4132-y","article-title":"Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users","volume":"28","author":"Eiken","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2022.05.003_bib96","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.joms.2021.12.007","article-title":"Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan","volume":"80","author":"Ishimaru","year":"2022","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib97","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2022.05.003_bib98","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A\u00a0randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib99","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.afos.2022.05.003_bib100","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 Years","volume":"104","author":"Watts","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.afos.2022.05.003_bib101","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis\u2013free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib102","first-page":"1","article-title":"Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw","volume":"78","author":"Troeltzsch","year":"2012","journal-title":"J\u00a0Can Dent Assoc"},{"key":"10.1016\/j.afos.2022.05.003_bib103","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.afos.2022.05.003_bib104","series-title":"Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib-a case report with clinical implications","year":"2013"},{"key":"10.1016\/j.afos.2022.05.003_bib105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","article-title":"A\u00a0rare case of osteonecrosis of the jaw related to imatinib","volume":"43","author":"Viviano","year":"2017","journal-title":"J\u00a0Korean Assoc Oral Maxillofac Surg"},{"key":"10.1016\/j.afos.2022.05.003_bib106","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.oooo.2020.10.005","article-title":"Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report","volume":"131","author":"Gupta","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.afos.2022.05.003_bib107","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.5301\/tj.5000504","article-title":"Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma","volume":"102","author":"Garuti","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.afos.2022.05.003_bib108","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","article-title":"Axitinib-related osteonecrosis of the jaw","volume":"124","author":"Patel","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.afos.2022.05.003_bib109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omsc.2017.03.001","article-title":"Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient","volume":"3","author":"Jung","year":"2017","journal-title":"Oral and Maxillofacial Surgery Cases"},{"key":"10.1016\/j.afos.2022.05.003_bib110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust Dent J"},{"key":"10.1016\/j.afos.2022.05.003_bib111","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort","volume":"125","author":"Abel Mahedi Mohamed","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.afos.2022.05.003_bib112","first-page":"20","article-title":"Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?","volume":"4","author":"Giancola","year":"2013","journal-title":"Ann Stomatol"},{"key":"10.1016\/j.afos.2022.05.003_bib113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.23937\/2469-5734\/1510033","article-title":"Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report","volume":"2","author":"Lee","year":"2016","journal-title":"Int J Oral Dent Health"},{"key":"10.1016\/j.afos.2022.05.003_bib114","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2016.1100","article-title":"Osteonecrosis of the jaw associated with everolimus: a case report","volume":"6","author":"Yamamoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.afos.2022.05.003_bib115","first-page":"401","article-title":"Osteonecrosis of the jaw in a patient treated with denosumab and temsirolimus","volume":"4","author":"Nifos\u00ec","year":"2017","journal-title":"SAJ Case Rep"},{"key":"10.1016\/j.afos.2022.05.003_bib116","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.oooo.2017.09.005","article-title":"Methotrexate-associated osteonecrosis of the jaw: a report of two cases","volume":"124","author":"Henien","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.afos.2022.05.003_bib117","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1210\/jc.2002-020780","article-title":"Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism","volume":"87","author":"Palomba","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525522000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525522000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:35:10Z","timestamp":1762500910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525522000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2405525522000267"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2022.05.003","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of sex steroids on osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}